Efzimfotase Alfa Demonstrated Improvements in Bone Health in Treatment-Naive Pediatric Patients With Hypophosphatasia Achieving Median Difference of 1.67 vs. Placebo in RGI-C Score at Week 25 in MULBERRY Phase III Trial
June 30, 2026
June 30, 2026
WILMINGTON, Delaware, June 30 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Efzimfotase alfa demonstrated improvements in bone health in treatment-naIve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Efzimfotase alfa demonstrated favorable safety profile and tolerability in treatment -naive patients and those switching from . . .
* * *
Efzimfotase alfa demonstrated improvements in bone health in treatment-naIve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
Efzimfotase alfa demonstrated favorable safety profile and tolerability in treatment -naive patients and those switching from . . .